Hookipa Pharma Inc. (HOOK) — 8-K Filings

8-K Filings (18)

• HOOKIPA Pharma Files 8-K on Security Holder Vote Matters — Jul 29, 2025 Risk: low
  HOOKIPA Pharma Inc. filed an 8-K on July 29, 2025, to report on the submission of matters to a vote of security holders. The filing does not contain specific de
• HOOKIPA Pharma Inc. Faces Delisting Notice — Jul 18, 2025 Risk: high
  HOOKIPA Pharma Inc. filed an 8-K on July 18, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The filing also includes other
• HOOKIPA Pharma Inc. Files 8-K with Material Agreements and Officer Changes — May 22, 2025 Risk: medium
  HOOKIPA Pharma Inc. announced on May 21, 2025, the entry into a material definitive agreement and the termination of another. The company also reported the depa
• HOOKIPA Pharma Inc. Files 8-K — Feb 20, 2025 Risk: low
  HOOKIPA Pharma Inc. filed an 8-K on February 20, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its principal
• HOOKIPA Pharma Files 8-K — Jan 29, 2025 Risk: low
  HOOKIPA Pharma Inc. filed an 8-K on January 29, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain sp
• HOOKIPA Pharma Files 8-K — Jan 10, 2025 Risk: low
  HOOKIPA Pharma Inc. filed an 8-K on January 10, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific det
• HOOKIPA Pharma Files 8-K with Corporate Details — Jan 7, 2025 Risk: low
  HOOKIPA Pharma Inc. filed an 8-K on January 7, 2025, reporting other events and financial statements. The filing details the company's principal executive offic
• HOOKIPA Pharma Inc. Files 8-K for Rule 14a-12 Compliance — Jan 2, 2025 Risk: low
  HOOKIPA Pharma Inc. announced on January 2, 2025, that it is filing this Form 8-K to satisfy its reporting obligations under Rule 14a-12 of the Exchange Act. Th
• Roche to Acquire HOOKIPA Pharma for $300M — Nov 20, 2024 Risk: medium
  HOOKIPA Pharma Inc. announced on November 18, 2024, that it has entered into a definitive agreement to be acquired by Roche for $300 million in cash. This acqui
• HOOKIPA Pharma Elects New Directors, Files Exhibits — Aug 30, 2024 Risk: medium
  HOOKIPA Pharma Inc. announced on August 27, 2024, a change in its board of directors, with the election of Dr. Jonathan Lim and Dr. David Sidransky as Class II
• HOOKIPA Pharma Appoints New CMO and CSO, CMO Departs — Jul 26, 2024 Risk: medium
  HOOKIPA Pharma Inc. announced on July 22, 2024, the appointment of Dr. Jonathan R. Hepple as Chief Medical Officer and Dr. Michael J. Yost as Chief Scientific O
• HOOKIPA Pharma Inc. Files 8-K with Corporate Updates — Jul 10, 2024 Risk: low
  HOOKIPA Pharma Inc. filed an 8-K on July 10, 2024, reporting material modifications to security holder rights and amendments to its articles of incorporation or
• HOOKIPA Pharma Files 8-K on Corporate Actions — Jun 18, 2024 Risk: low
  HOOKIPA Pharma Inc. filed an 8-K on June 17, 2024, reporting on several key corporate events. These include amendments to its articles of incorporation or bylaw
• Roche to Acquire HOOKIPA Pharma for $300M — Jun 4, 2024 Risk: medium
  HOOKIPA Pharma Inc. announced on June 4, 2024, that it has entered into a definitive agreement to be acquired by Roche for $300 million in cash. This acquisitio
• Roche to Acquire HOOKIPA Pharma for $1.7 Billion — May 23, 2024 Risk: medium
  HOOKIPA Pharma Inc. announced on May 23, 2024, that it has entered into a definitive agreement to be acquired by Roche for $8.00 per share in cash, representing
• HOOKIPA Pharma Inc. Files 8-K — Apr 25, 2024 Risk: low
  HOOKIPA Pharma Inc. filed an 8-K on April 25, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain s
• HOOKIPA Pharma Receives Nasdaq Delisting Notice for Low Bid Price — Jan 31, 2024
  HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced on January 31, 2024, that it received a delisting notice from The Nasdaq Global Select Market because its common st
• HOOKIPA Pharma Terminates Key Agreement, Signals Impairments — Jan 29, 2024
  HOOKIPA Pharma Inc. filed an 8-K on January 29, 2024, reporting an event on January 25, 2024, related to the termination of a material definitive agreement. Thi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX